Albumin Removal from Sample Preparations

Albumin Removal from Sample Preparations

Biotech Support Group bring you two alternate strategies for albumin removal from sample preparations:

AlbuSorb – an albumin binding strategy

AlbuVoid – an albumin voiding strategy

plus Albutrial, a combined trial kit including 1 gm of AlbuSorb™ and 5 Preps of AlbuVoid™ with respective buffers.

AlbuSorb™ is an albumin depletion kit allowing albumin removal from serum or plasma.  AlbuSorb™ comes from a class of solid-phase, or surface-based, elastomeric poly-electrolytic surfaces that bind proteins through an empirically derived chemistry combining elements of polymer composition, cross-linking architecture and charge properties. As with bio-polymers like DNA and Heparin, governing their reactivity is the spatial presentation of the electrostatic groups along a flexible polymer chain. Unlike immuno-affinity, the surfaces utilized are disposable eliminating cycle to cycle variance and cross-contamination. AlbuSorb™ is supplied as a powder. Simply weigh, centrifuge and/or filter, and recover the albumin depleted serum in the supernatant.

Key Features of AlbuSorb

  • Removes 30 mg albumin/ml, >90%
  • Affinity-type equivalence, virtually no cross-reactivity with other proteins
  • Disposable, no column regeneration or cross-contamination
  • Economical new surface technology, not based on blue-dye or immuno-affinity chromatography
  • Mild binding conditions maintains tertiary structure and simple transfer to secondary analysis
  • The flow-through (unbound) fractions retain their enzymatic and biological activity Removes albumin from most species including human, sheep, bovine, mouse, goat, rat, and calf.

AlbuVoid™ is an albumin depletion reagent kit which removes albumin from serum and plasma samples whilst concentrating low abundance/low molecular weight proteins. The AlbuVoid™ protocol uses mild buffers; the protocol conditions are so gentle that native enzyme activity is retained in elution fractions. AlbuVoid™ considerably enhances resolution of proteins below 50 kD, a limitation of alternate enrichment protocols.

AlbuVoid™ does not bind albumin. All other proteins (except albumin) in the sample binds to AlbuVoid™ , allowing the user to elute off all the proteins except albumin providing a low abundance serum protein enrichment. It is ideal for applications involving biomarker discovery, enzyme assays, toxicological studies for new drugs, protein profiling using SELDI analysis, protein array pixelation ,1D and 2D gel electrophoresis, LC/MS, and MALDI-TOF MS and cytokine research.

Key Features of AlbuVoid™ 

  • Albumin voids in flow-through >95%, with <30 minute bind/wash/elute protocol
  • Low abundance enrichment equivalent or better than hexa-peptides or antibodies
  • Disposable, cost-effective, no column regeneration or cross-contamination
  • Mild elution maintains tertiary structure and simple transfer to secondary analysis
  • The eluted fractions retain their enzymatic and biological activity
  • Removes albumin from many species including human, mouse, sheep, bovine, goat, rat, calf, cell culture.
  • The eluted fraction is compatible with LC-MS, activity based protein profiling and proteomic studies.

Albuvoid

AlbuVoid™ derives from a silica-based library of individual mixed-mode polymeric ligands. The library was designed to facilitate weak binding of proteins, allowing for rapid elution from the matrix without any foreknowledge of the variety of proteins contained in the starting sample. Because of its specific binding properties, AlbuVoid™ depletes high abundance proteins in serum like albumin while improving the resolution of less abundant serum proteins.

Product Information

Product Name Size Total Samples Processed Product Code
AlbuVoid™ 5 Preparations 5 x 200µl samples AVK-05
AlbuVoid™ 10 Preparations 10 x 200µl samples AVK-10
AlbuVoid™ 50 Preparations 50 x 200µl samples AVK-50
For Bulk Enquiries, please contact mailto:techsupport@caltagmedsystems.co.uk

Caltag Medsystems are the UK distributor for Biotech Support Group. For further information about their products, please contact us and we will be happy to help.

Get In Touch

References

AlbuSorb:

Cerebrospinal Fluid Gwenael Pottiez, Pawel Ciborowski. Proteomic Profiling of Cerebrospinal Fluid Expression Profiling In Neuroscience Neuromethods.2012;64:245-270 Synovial fluid Happonen KE, Fürst CM, Saxne T et al.

PRELP protein inhibits the formation of the complement membrane attack complex.Journal of Biological Chemistry.2012;287(11):8092-100 Serum Holmberg R, Refai E, Höög A.Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proceedings of the National Academy of Sciences.2011;108(26):10685-9. Tang MX, Ogawa K, Asamoto M.

Effects of Nobiletin on PhIP-Induced Prostate and Colon Carcinogenesis in F344 Rats Nutrition and Cancer.2011;63(2):227-33 Holmberg, Rebecka Apolipoprotein CIII and Ljungan virus in diabetes 2010. Doctoral Thesis Lu Q, Zheng X, McIntosh T

Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Analytical Chemistry.2009;81(21):8715-23 Urine Zubiri, Irene, et al.

Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. Journal of Proteomics (2013). Patent Berggren, Per Olaf, Yang, Shao-Nian. 2012. Methods For Treating And/Or Limiting Development Of Diabetes.U.S. Patent 20120328630 Kind Code: A1, filed June 25, 2012, and issued December 27,

AlbuVoid:

Sun, Zhenyu, Xiaofeng Chen, Gan Wang, Liang Li, Guofeng Fu, Matthew Kuruc, and Xing Wang. “Identification of functional metabolic biomarkers from lung cancer patient serum using PEP technology.” Biomarker Research 4, no. 1 (2016): 1.

Haiyan Zheng; Caifeng Zhao; Swapan Roy; Devjit Roy MD; Amenah Soherwardy; Ravish Amin; Matthew Kuruc. Application Report – The Comparison of the Serum Proteome in Individuals with Cancers versus those without Cancer, and its application to Wellness

Dr.Swapan Roy; Amenah Soherwardy; Ravish Amin; Matthew Kuruc.Monmouth Junction, NJ – Application Report. AlbuSorb™ Product Extension combines Albumin and Immunoglobulin Depletion in a Consumable Format

Xing Wang, Michael Davies, Swapan Roy and Matthew Kuruc. Bead Based Proteome Enrichment Enhances Features of the Protein Elution Plate (PEP) for Functional Proteomic Profiling . Proteomes 2015, 3(4), 454-466 . doi: 10.3390/proteomes3040454

Haiyan Zheng, Caifeng Zhao, Meiqian Qian, Swapan Roy, Absari Arpa, Amenah Soherwardy and Matthew Kuruc. AlbuVoid™ Coupled to On-Bead Digestion – Tackling the Challenges of Serum Proteomics. J Proteomics Bioinform 2015, 8:9.
Kuruc Matt, Dr.Roy. Application Report – AlbuVoid™ LC-MS On-Bead – Differential Expression of Cancer Sera Proteins Using Quantitative (iTRAQ) Proteomics

Grubbs, J. K., et al. ” Investigation of the efficacy of albumin removal procedures on porcine serum proteome profile1.” (2015).

Serum Profiling Making Mark on Predictive Medicine Vicki Glaser.Genetic Engineering & Biotechnology News. 2011;31(7):1-55.

AlbuVoid™ with Plasma:

Espes, Daniel, Joey Lau, and Per-Ola Carlsson. ” AIncreased circulating levels of betatrophin in individuals with long-standing type 1 diabetes.” Diabetologia(2013): 1-4.

Patent – Secretome Sample Preparation

Narain, Niven Rajin, and Paula Patricia Narain. ” COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER.” U.S. Patent No. 20,150,023,949. 22 Jan. 2015.

Narain, Niven Rajin, Rangaprasad Sarangarajan, and Vivek K. Vishnudas. ” INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF.” U.S. Patent No. 20,120,258,874. 11 Oct. 2012.

 

 

Albumin Removal from Sample Preparations